Today’s Research Reports on Trending Tickers: CRISPR Therapeutics and Incyte

NEW YORK, NY / ACCESSWIRE / June 27, 2018 / U.S. markets rebounded on Tuesday after experiencing steep losses the past week due to growing trade tensions. The Dow Jones Industrial Average increased 0.12 percent to close at 24,283.11, while the S&P 500 Index gained 0.22 percent to close at 2,723.06. The Nasdaq Composite Index jumped 0.39 percent to close at 7,561.63.

“The market is trading more on sentiment than fundamentals lately, which means moves are likely to be fickle and short lived,” said Liz Young, senior investment strategist at BNY Mellon Investment Management, according to MarketWatch.

“We feel that while momentum around trade is escalating, we’re still in a place where it’s in every nation’s best interest to avoid that outcome, and that things could calm down as negotiations progress,” she said. “In the meantime, the economy is still strong, data is moving in the right direction, and we don’t see this as the issue that will turn things around.”

RDI Initiates Coverage on:

CRISPR Therapeutics AG
https://rdinvesting.com/news/?ticker=CRSP

Incyte Corporation
https://rdinvesting.com/news/?ticker=INCY

CRISPR Therapeutics’ stock jumped 3.94% Tuesday, to close the day at $64.10. The stock recorded a trading volume of 702,230 shares, which was below its three months average volume of 1,629,867 shares. In the last year, CRISPR Therapeutics’ shares have traded in a range of 15.55 – 73.90. The share price has gained 312.22% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $62.52 is above its 200-day moving average of $45.73. Shares of CRISPR Therapeutics have fallen roughly 8.35 percent in the past month and are up 173 percent year-to-date.

Access RDI’s CRISPR Therapeutics AG Research Report at:
https://rdinvesting.com/news/?ticker=CRSP

On Tuesday, shares of Incyte recorded a trading volume of 4,064,585 shares, which was above the three months average volume of 2,653,875 shares. The stock ended the day 6.97% lower at $66.73. The share price has fallen 52.37% from its 52 week high with a 52 week trading range of 60.23 – 140.11. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $68.65 is below its 200-day moving average of $81.24. Shares of Incyte have fallen roughly 2.48 percent in the past month and are down 29.54 percent year-to-date.

Access RDI’s Incyte Corporation Research Report at:
https://rdinvesting.com/news/?ticker=INCY

Our Actionable Research on CRISPR Therapeutics AG (NASDAQ:CRSP) and Incyte Corporation (NASDAQ:INCY) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 503877